Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.